Or­biMed rais­es $4.3B across three funds to in­vest in biotech com­pa­nies, as well as roy­al­ty deals and Chi­na star­tups

Or­biMed said Tues­day it has raised over $4.3 bil­lion across three new funds to in­vest in pub­lic and pri­vate biotechs amid a lengthy mar­ket down­turn.

The New York-based hedge fund is one of the world’s largest health­care in­vestors, with about $18 bil­lion in as­sets un­der man­age­ment. It took a lit­tle over a year to raise these three new funds: Or­biMed Pri­vate In­vest­ments IX, Or­biMed Asia Part­ners V, and Or­biMed Roy­al­ty & Cred­it Op­por­tu­ni­ties IV. Or­biMed’s part­ners told End­points News these new funds will like­ly sup­port at least 75 com­pa­nies over­all, as it sees many op­por­tu­ni­ties in a bear­ish mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER